Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Gilead Sciences (GILD): Pioneering Long-Acting HIV Therapies with Lenacapavir – What’s the Growth Potential, Pipeline Outlook & its 5 Key Catalysts?
Gilead Sciences delivered a robust performance in Q3 2024, driven by strong growth in its HIV franchise. Biktarvy maintained its leadership with a 13% YoY revenue increase, and Descovy for PrEP posted 15% growth, reflecting rising demand for prevention solutions. The anticipated launch of lenacapavir for PrEP is set to expand the U.S. market and enhance Gilead's leadership in HIV prevention. In oncology, Trodelvy showed strong momentum, although the discontinuation of second-line NSCLC development caused a temporary sentiment drag. Despite sequential sales declines in cell therapy, Gilead's strategic pivot towards expanding CAR-T in community settings remains crucial for long-term success. The company raised its FY24 guidance, reflecting strong operational execution and disciplined cost management. Gilead’s focus on transformative therapies, such as lenacapavir, Trodelvy, and anito-cel, is progressing well. With a goal of achieving 10 transformative launches by 2030, Gilead’s pipeline remains a key growth driver. While competitive dynamics in CAR-T and payer-driven challenges could pose risks, Gilead’s strategic priorities and strong fundamentals support its growth trajectory. We maintain our “Outperform” rating, confident in Gilead’s diversified growth. What will be the impact of lenacapavir’s launch on Gilead’s long-term growth, and how will it influence the company's valuation outlook?
